Eli Lilly (LLY) - Fundamental Analysis Report 2026 (Updated)
Dear Readers, Welcome to Deep Research Global.
Let’s analyze the topic in detail.
Executive TL;DR
Eli Lilly (LLY) posted Q1 2026 revenue of $19.8 billion, a 56% jump driven by 65% volume growth from Mounjaro and Zepbound, and raised full-year 2026 revenue guidance to a range of $82 billion to $85 billion.
The incretin franchise (Mounjaro plus Zepbound) generated $12.8 billion in Q1 2026 alone, representing about 65% of total quarterly revenue, with Mounjaro up 125% and Zepbound up 80% year over year.
The April 2026 FDA approval of Foundayo (orforglipron) gives Lilly the first once-daily oral GLP-1 pill for obesity that requires no food or water restrictions, opening a major new addressable market.
Risks include MFN pricing pressure, IRA Medicare negotiation, and intensifying late-stage obesity competition from Novo Nordisk, Amgen, Roche, and Pfizer, but the diversified pipeline and roughly $50 billion in US manufacturing capacity buildout since 2020 form a strong moat.
Recommended - Read Full Reports
Read All Reports
Table of Contents
Executive TL;DR
Introduction
Eli Lilly Company Profile: Key Facts
Eli Lilly Investment Thesis (LLY)
Pillar 1: Incretin Volume Compounding
Pillar 2: Foundayo Optionality
Pillar 3: Retatrutide Upside
Pillar 4: Manufacturing Scale Moat
Pillar 5: Pipeline Diversification
Eli Lilly Business Model Overview
How Lilly Generates Revenue
Therapeutic Portfolio Structure
Operating Leverage and Margin Profile
Eli Lilly Revenue Analysis
Headline Numbers
Quarterly Revenue Cadence
Geographic Mix
Q1 2026 Earnings Guidance and Forward Outlook
2026 Full-Year Guidance Reset
Earnings Quality
Margins, Earnings Quality, and EPS Trajectory
Gross Margin Story
Operating Margin Expansion
EPS Trajectory Forward View
Cash Flow Mechanics
Operating Cash Flow
Capital Expenditure Intensity
Free Cash Flow Conversion
Balance Sheet Health
Debt Structure and Leverage
Capital Allocation Hierarchy
Shareholder Returns
Eli Lilly Segment-by-Segment Teardown
Cardiometabolic Health Segment
Mounjaro
Zepbound
Trulicity
Jardiance
Foundayo
Oncology Segment
Verzenio
Jaypirca
Inluriyo
Immunology Segment
Neuroscience Segment
Major Eli Lilly Competitors
Eli Lilly vs Novo Nordisk
Eli Lilly vs Pfizer
Eli Lilly vs Amgen
Eli Lilly vs Roche
Eli Lilly vs AstraZeneca
Eli Lilly vs Merck
Eli Lilly Strategic Context
Macro Position in Pharmaceutical Industry
Regulatory and Political Backdrop
Manufacturing as Strategy
Business Development Strategy
Eli Lilly Valuation Framework
Multiple-Based Valuation
DCF Considerations
Sum-of-the-Parts View
What the Market Is Pricing
Bull, Base, and Bear Case Scenario Analysis for Eli Lilly
Bull Case
Base Case
Bear Case
Key Risks for Eli Lilly
Risk 1
Risk 2
Risk 3
Risk 4
Risk 5
Risk 6
Risk 7
Catalysts to Watch
Near-Term Catalysts (2026)
Mid-Term Catalysts (2027)
Longer-Term Catalysts (2028+)
Additional Strategic Considerations for Investors
The LillyDirect Channel Evolution
Real-World Evidence and Outcomes Data
Geographic Expansion Cadence
The Compounding Pharmacy Issue
My Final Thoughts
Latest Analyst Price Targets
Official Sources and Data
Disclaimer: This analysis is for informational & educational purposes only and should not be construed as investment advice. Investors should conduct their own due diligence before making investment decisions. Past performance does not guarantee future results.
Introduction
Eli Lilly (LLY) just closed the loop on the most consequential year in its 150-year history.
The company crossed $65 billion in annual revenue for 2025, raised 2026 sales guidance for the third time in two quarters, and won FDA approval for Foundayo, the first oral GLP-1 pill cleared for chronic weight management without timing or hydration restrictions.
For investors trying to understand a $1 trillion-scale story before it becomes a $2 trillion one, three numbers matter: $19.8 billion in Q1 2026 revenue, $50 billion in committed US manufacturing investment, and a pipeline spanning retatrutide, Imlunestrant, Kisunla, and four newly acquired biotech platforms.
Eli Lilly Company Profile: Key Facts Snapshot
Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly in Indianapolis, Indiana, and operates as one of the world’s oldest pharmaceutical innovators.
The company today develops and markets prescription medicines across diabetes, obesity, oncology, immunology, neuroscience, and other therapy areas.
Headquartered at Lilly Corporate Center in Indianapolis, the company employs roughly 47,000 people across more than 100 countries, with major research hubs in the United States, China, the United Kingdom, and Germany.
Snapshot of Eli Lilly and Company
- Ticker: NYSE: LLY
- Founded: 1876 (Indianapolis, IN)
- CEO: David A. Ricks (since January 2017)
- Q1 2026 Revenue: $19.8 billion
- FY 2025 Revenue: $65.18 billion
- 2026 Revenue Guidance: $82.0B to $85.0B
- Employees: ~47,000
- Recent Share Price (May 22, 2026): $1,065.00
- Market Capitalization: ~$888 billion
- Q1 2026 Dividend: $1.73 per share
The leadership team includes Chairman and CEO David A. Ricks, Chief Financial Officer Lucas Montarce, and Chief Scientific Officer Dr. Daniel Skovronsky. Together they have steered the company through the post-2020 incretin boom and the transition from a legacy diabetes franchise toward a fully diversified specialty pharma model.
Lilly’s most consequential brands today include Mounjaro (tirzepatide) for type 2 diabetes, Zepbound (tirzepatide) for chronic weight management, Verzenio (abemaciclib) for HR+/HER2- breast cancer, Jaypirca (pirtobrutinib) for select B-cell malignancies, Kisunla (donanemab) for early symptomatic Alzheimer’s disease, and the newly launched Foundayo for obesity.
Eli Lilly Investment Thesis (LLY)
The investment thesis on Lilly today rests on five pillars that are unusually well aligned.
Pillar 1: Incretin Volume Compounding
Tirzepatide is the single most successful pharmaceutical launch in history.
In its third commercial year as Mounjaro and second as Zepbound, the molecule generated $36.5 billion in combined 2025 revenue and another $12.8 billion in Q1 2026 alone.
Volume growth, rather than price, is doing the heavy lifting.
Q1 2026 revenue rose 56% with 65% volume expansion offset by a 13% price decline, signaling that demand for the franchise is far from saturated even as the company absorbs Medicaid rebates and most-favored-nation pricing concessions.
Tirzepatide Franchise Revenue Build
- 2022: $0.48B (Mounjaro launch)
- 2023: $5.34B combined
- 2024: $16.47B combined
- 2025: $36.51B combined
- Q1 2026: $12.82B (annualized run rate ~$51B+)
Pillar 2: Foundayo Optionality
The April 1, 2026 approval of Foundayo (orforglipron) gives Lilly the only oral GLP-1 pill that does not require fasting or water restrictions, addressing patients who cannot or will not use injectables.
In the ATTAIN-1 trial, participants on the highest dose lost 27.3 pounds (12.4% of body weight) on average when they completed treatment, versus 2.2 pounds (0.9%) on placebo.
The drug is launching at $149 per month for self-pay at the lowest dose, $25 monthly with the savings card for commercially insured patients, and $50 monthly for eligible Medicare Part D patients starting July 1, 2026.
Pillar 3: Retatrutide Upside
Retatrutide, Lilly’s triple agonist targeting GLP-1, GIP, and glucagon receptors, posted average weight loss of 28.3% (70.3 pounds) at 12 mg over 80 weeks in TRIUMPH-1, with 45.3% of participants achieving at least 30% weight loss.
A second pivotal study, TRIUMPH-4, showed 28.7% weight loss in patients with obesity and knee osteoarthritis, suggesting durable efficacy in real-world comorbid populations.
If retatrutide reaches the market in 2027 as expected, Lilly will be the first company with a portfolio spanning oral and injectable GLP-1 plus a next-generation tri-agonist.
Pillar 4: Manufacturing Scale Moat
Since 2020, Lilly has committed more than $50 billion to expand US manufacturing.
The most recent announcement, a $3.5 billion injectable plant in the Lehigh Valley, Pennsylvania, brings the company’s total domestic plant buildout to 11 facilities.
This capital deployment matters because the supply constraint that bottlenecked tirzepatide demand in 2023 and 2024 has been replaced by a manufacturing surplus that supports the simultaneous launch of Foundayo, the global rollout of Zepbound into roughly 30 additional countries, and the eventual launch of retatrutide.
Pillar 5: Pipeline Diversification
Beyond cardiometabolic, Lilly is building credible franchises in oncology (Verzenio, Jaypirca, Inluriyo), immunology (Taltz, Ebglyss, Omvoh), and neuroscience (Kisunla).
The Key Product revenue for these three areas grew 160% year over year in Q1 2026.
The four announced Q1 2026 acquisitions add capabilities in mRNA delivery (Orna), sleep-wake disorders (Centessa), in vivo CAR-T (Kelonia), and JAK inhibition for myeloproliferative neoplasms (Ajax).
The strategy mirrors the playbook large pharma has used for decades, but Lilly is executing it from a position of operating leverage rather than patent-cliff defense.
Eli Lilly Business Model Overview
Lilly operates as a vertically integrated pharmaceutical company that internally discovers, develops, manufactures, and commercializes prescription medicines.
The model is global in scope but anchored in the United States, which represented roughly 60% to 65% of revenue in recent quarters.
How Lilly Generates Revenue
The company sells branded prescription medicines under patent protection at premium prices through wholesalers, specialty pharmacies, and direct-to-consumer channels such as LillyDirect.
Revenue is recognized net of significant gross-to-net deductions including Medicaid rebates, commercial rebates, 340B discounts, and most-favored-nation reductions on GLP-1 products.
Direct distribution through LillyDirect, launched in January 2024, is becoming an increasingly important channel.
The platform sells single-dose vials of Zepbound at $349 to $599 monthly without insurance, and now also distributes Foundayo at launch prices that undercut the traditional retail markup.
Therapeutic Portfolio Structure
Lilly’s commercial footprint sits in five therapy areas.
Cardiometabolic Health, encompassing tirzepatide, Trulicity, Jardiance, Foundayo, Basaglar, Humalog, and Humulin, is the financial engine.
Oncology contains Verzenio, Jaypirca, Cyramza, and the recently approved Inluriyo. Immunology houses Taltz, Olumiant, Ebglyss, and Omvoh.
Neuroscience features Kisunla and Emgality. The fifth bucket includes legacy and partnered products in other areas.
Lilly's Therapy Area Architecture
1. Cardiometabolic Health (~75% of revenue)
- Mounjaro, Zepbound, Foundayo, Trulicity, Jardiance, Basaglar
2. Oncology (~12% of revenue)
- Verzenio, Jaypirca, Cyramza, Inluriyo, Retevmo
3. Immunology (~7% of revenue)
- Taltz, Olumiant, Ebglyss, Omvoh
4. Neuroscience (~3% of revenue)
- Kisunla, Emgality
5. Other (~3% of revenue)
- Forteo, Cialis (partnered), Cymbalta legacyOperating Leverage and Margin Profile
Lilly’s gross margin reached 81.9% on a reported basis and 82.6% on a non-GAAP basis in Q1 2026, reflecting the high-margin nature of branded biologics and small molecules. Performance margin guidance for full-year 2026 sits at 47.0% to 48.5%, a level few diversified pharmaceutical companies can match.
R&D intensity has compressed from 27.3% of revenue in 2023 to roughly 20.5% in 2025, not because absolute spending fell, but because revenue is growing faster than the research budget.
Absolute R&D spending rose 21% in 2025 to $13.3 billion, then accelerated again in Q1 2026 with R&D up 28% to $3.5 billion.
Eli Lilly Revenue Analysis
The revenue line is where Lilly’s transformation is most visible.
The company went from $24.5 billion in 2020 to $65.2 billion in 2025, with guidance for $82 to $85 billion in 2026. That’s roughly $60 billion of incremental revenue in six years, an achievement essentially unprecedented in pharmaceutical history.
Headline Numbers
Worldwide revenue in Q1 2026 increased 56% to $19.8 billion, driven by 65% volume growth, partially offset by a 13% reduction in realized prices.
US revenue rose 43% to $12.1 billion, with volume up 49% and prices down 7%. International revenue jumped 81% to $7.7 billion, supported by